TRAF4

TRAF4 Full Name

TNF receptor-associated factor 4

TRAF4 Introduction

TRAF4 (TNF receptor-associated factor 4) is a unique member of the TRAF family of adaptor proteins and E3 ubiquitin ligases, attracting increasing attention because of its dual roles in normal development and human disease. Unlike several other TRAF proteins primarily involved in inflammatory signaling, TRAF4 participates in diverse cellular processes including embryonic development, epithelial cell polarity maintenance, cell proliferation, apoptosis regulation, and oxidative stress responses. Structurally, TRAF4 contains a RING finger domain with ubiquitin ligase activity, multiple zinc finger motifs, and a TRAF domain that mediates protein–protein interactions, allowing it to regulate downstream signaling networks. For researchers investigating cancer-related signaling abnormalities, TRAF4 has emerged as an important molecular node because dysregulated TRAF4 expression can reshape multiple pathways, including NF-κB, PI3K/AKT, Wnt/β-catenin, and TGF-β signaling, which are frequently associated with tumor progression and therapeutic resistance.

Growing evidence indicates that TRAF4 functions as an oncogenic regulator in multiple malignancies by controlling protein stability, transcriptional activity, and metastatic signaling. TRAF4 overexpression has been reported in breast cancer, lung cancer, liver cancer, glioblastoma, and other solid tumors, where it promotes tumor cell proliferation, migration, invasion, and survival. Mechanistically, TRAF4 enhances TGF-β receptor signaling by facilitating receptor complex activation, promoting K63-linked ubiquitination events, and preventing Smurf2-mediated receptor degradation, thereby contributing to cancer metastasis. In glioblastoma, TRAF4 supports tumor growth by interacting with SETDB1 and maintaining SETDB1 stability through atypical ubiquitination, resulting in sustained AKT pathway activation. These findings highlight TRAF4 as more than a passive biomarker; it acts as a signaling regulator that connects ubiquitination machinery with major cancer-driving pathways, making it a potential target for studying tumor progression and resistance mechanisms.

Recent studies have further expanded the therapeutic relevance of TRAF4, particularly in advanced and treatment-resistant cancers. In metastatic prostate cancer, TRAF4 has been shown to regulate androgen receptor (AR) signaling through atypical K27-linked ubiquitination of the AR C-terminal region, enhancing AR interaction with the pioneer transcription factor FOXA1 and promoting transcriptional reprogramming associated with castration-resistant prostate cancer (CRPC). Across different tumor types, elevated TRAF4 expression is frequently correlated with aggressive disease characteristics and poor clinical outcomes, suggesting its potential value as a prognostic biomarker and drug discovery target. However, the complexity of TRAF4 biology, including its context-dependent effects in development, immunity, and cancer, remains a challenge for researchers seeking selective therapeutic strategies. Understanding TRAF4-mediated ubiquitination events and pathway-specific functions may provide new opportunities for developing targeted interventions against cancers driven by abnormal signaling regulation.

Alternate Names for TRAF4

TRAF4; TNF receptor-associated factor 4; CART1; MLN62; RNF83; MLN 62; malignant 62; RING finger protein 83; metastatic lymph node gene 62 protein; tumor necrosis receptor-associated factor 4A

View more

• 1.Ruan X, et al.;The Research Progress in Physiological and Pathological Functions of TRAF4. Front Oncol. 2022, 2:842072.
  2.Gan L, et al.; The role of ubiquitination and deubiquitination in urological tumours. Front Pharmacol. 2025, 16:1532878.